• Tested with 10-2  As many abnormal 10-2 hemifields (53%) as abnormal 24-2 hemifields (59%).
 Of the eyes with normal 24-2 hemifields, 16% were classified as abnormal with the 10-2 test  Of the abnormal 10-2 hemifields, 68%, 8%, and 25% were arcuatelike, widespread, and other, respectively  Superior VF defects were deeper and closer to fixation than those in the inferior VF Traynis I, JAMA Oph 2014;132 (3):291-297.
 The 10-2 VF was abnormal in nearly as many hemifields as was the 24-2 VF, including some with normal 24-2 VF, suggesting that the 24-2 test is not optimal for detecting early damage of the macula.
 The pattern of the defects was in agreement with a recent model of macular damage.
 Compare the efficacy of 10-2 vs. 24-2 VFs in detecting progression of initial parafoveal scotoma (IPFS) in glaucomatous eye  50 eyes followed for 5.7 years  Ave. of 7.7 VF's obtained  Mean global progression rate was significantly greater in 10-2 analysis (-0.40±0.51 dB/yr) than in 24-2 analysis (-0.23 ± 0.28 dB/yr) (P=0.01).
 Within the central 10 degrees of VF, 10-2 analysis detected significantly more progressing eyes than 24-2 analysis (24 vs. 7 eyes; P<0.001).
 Within the central 10 degrees, mean localized progression rate (-1.3 vs. -0.4 dB/yr) and mean number of progressing points (2.5 vs. 0.5) were significantly greater in 10-2 than in 24-2 analyses (10-2 vs. 24-2; all P<0.001).
 In glaucoma patients with an IPFS, the 10-2 VF detects more progressing eyes than the 24-2 VF, suggesting that closer surveillance of the central VF using 10-2 VF is warranted in these eyes. Mean Diurnal IOP Reduction from Baseline at the 12-Month Visit (N=65) c -6.4 ± 1.1 mmHg (-8.7, -4.2) a Study eyes undergoing glaucoma-related secondary surgical intervention and/or removal of XEN ® 45 Gel Stent prior to the 12-month evaluation were considered to be nonresponders. 1 Seven subjects in the study underwent needling procedures with mitomycin C; 4 of these subjects were considered responders. 1 b Primary effectiveness analysis using observed data and failure for subjects with glaucoma-related secondary surgical intervention and multiple imputations for missing data. 1 c Primary effectiveness analysis using observed data & worst within-eye IOP for subjects with glaucomarelated secondary surgical intervention and multiple imputations for missing data.  Review risks and benefits of possible medical and surgical treatment options  Do NOT promise that the patient will be able to stop some or all of their glaucoma medications  Continue current glaucoma medications through day of surgery  Confirm patient's VF, ONP and OCT are up to date  Gonioscopy -evaluating for synechia, iris processes, narrow anatomical angles, angle recession or any other abnormalities of the angle structure that may interfere with placement of the iStent
